LGR-3922

LGR-3922 is a preclinical, orally available, small‑molecule multi‑kinase inhibitor being developed as a targeted therapy for acute myeloid leukemia (AML) driven by KMT2A (MLL) rearrangements and FLT3 mutations. It was initially discovered at Palacky University and is characterized as a FLT3 modulator, G6PD inhibitor, and SRC family kinase inhibitor, providing a unique multi‑kinase mechanism aimed at suppressing leukemogenic signaling in KMT2A‑rearranged/FLT3‑mutant AML models.[3][5] In preclinical studies, LGR-3922 has shown rapid anti‑leukemic responses, superior tumor prevention and regression in KMT2A‑rearranged xenograft models, and reduction of leukemic colony formation at nanomolar concentrations, supporting its potential as a next‑generation targeted agent for this high‑risk AML subset.[2][3][9]